Faculty profile

Sylvain Meloche

ResearcherInstitut de recherche en immunologie et cancerUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses may be missing. Find their university profile.

Sylvain Meloche

Researcher

Institut de recherche en immunologie et cancer

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
16 publications in the last five years, latest in 2026.
Senior (last) author on 10 recent papers, a sign of leading a research group.
Principal investigator on 13 research grants (10 CIHR, 3 NSERC), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Map Kinases Signal Transduction Basal-Like Breast Cancer Chemoresistance Erk3 Genetically-Engineered Mouse Models Hypoxia Metastasis

Latest papers

The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer.
Oncogene · 2026
A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.
bioRxiv : the preprint server for biology · 2026
CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability.
Cell reports · 2025

All 59 publications

Latest funding

Live cell imaging platform for the mechanistic analysis of cell differentiation, migration and division
NSERC · 2024 · Co-investigator
$150,000
Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression
CIHR · 2024 · Nominated PI
$1,013,626
Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression
CIHR · 2023 · Nominated PI
$100,000

All 19 grants and awards

59 publications.

The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer.

Acevedo M, Dô F, El-Mortada F, Tanguay PL, Voisin L, Houles T, Lavoie G, Allard D, Roux PP, Stagg J, Doré S, Walsh L, Fourtounis J, Bonneil E, Meloche S, Servant MJ

Oncogene2026

DOI: 10.1038/s41388-026-03695-y PMID: 41714442

A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.

Coulombe-Huntington J, Bertomeu T, Huard C, Chatr-Aryamontri A, St-Cyr DJ, Sánchez-Osuna M, Papadopoli D, Normandin K, Paydar M, McLaughlan S, St-Denis C, Zhang L, Say H, Palou R, Stark C, Breitkreutz BJ, van der Sloot AM, Manohar S, Lavoie H, Borden KLB, Raught B, D'Amours D, Sicheri F, Verreault A, Mader S, Meloche S, Therrien M, Thibault P, Wilhelm B, Dirks PB, Aitchison JD, Patton E, King RW, Roux PP, Sauvageau G, Hoang T, Marinier A, Harrington L, Kwok B, Archambault V, Topisirovic I, Tyers M

bioRxiv : the preprint server for biology2026

DOI: 10.64898/2026.01.28.701823 PMID: 41659671

CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability.

Boucher J, Houles T, Berliocchi E, Lavoie G, MacLeod G, Saba-El-Leil MK, Angers S, Meloche S, Roux PP

Cell reports2025

DOI: 10.1016/j.celrep.2025.116495 PMID: 41176765

Intracellular pH regulates ubiquitin-mediated degradation of the MAP kinase ERK3.

Tesnière C, Boudghene-Stambouli F, Severin M, Poët M, Voisin L, Ponniah M, Pascariu M, Bonneil E, Trempe JF, Thibault P, Counillon L, Pedersen SF, Meloche S

Proceedings of the National Academy of Sciences of the United States of America2025Senior author

DOI: 10.1073/pnas.2501825122 PMID: 41123996

ERK3/MAPK6 promotes triple-negative breast cancer progression through collective migration and EMT plasticity.

Morazzo S, Fernandes S, Fortea M, Skálová H, Pereira-Sousa D, Cassani M, Vrzalová K, Kafka F, Vrbský J, Soulez M, Meloche S, Morten-Seternes O, Bosáková V, Shin J, Frič J, Haase K, Forte G

Frontiers in oncology2025

DOI: 10.3389/fonc.2025.1563969 PMID: 40936697

Brain-wide mapping of immune receptors uncovers a neuromodulatory role of IL-17E and the receptor IL-17RB.

Lee Y, Ishikawa T, Lee H, Lee B, Ryu C, Davila Mejia I, Kim M, Lu G, Hong Y, Feng M, Shin H, Meloche S, Locksley RM, Koltsova E, Grivennikov SI, Heiman M, Choi GB, Huh JR

Cell2025

DOI: 10.1016/j.cell.2025.03.006 PMID: 40199322

Syngeneic mouse model of YES-driven metastatic and proliferative hepatocellular carcinoma.

Voisin L, Lapouge M, Saba-El-Leil MK, Gombos M, Javary J, Trinh VQ, Meloche S

Disease models & mechanisms2024Senior author

DOI: 10.1242/dmm.050553 PMID: 39051113

Phosphoproteomic analysis identifies supervillin as an ERK3 substrate regulating cytokinesis and cell ploidy.

Javary J, Goupil E, Soulez M, Kanshin E, Bouchard A, Seternes OM, Thibault P, Labbé JC, Meloche S

Journal of cellular physiology2024Senior author

DOI: 10.1002/jcp.30938 PMID: 36576983

A renaissance for YES in cancer.

Lapouge M, Meloche S

Oncogene2023Senior author

DOI: 10.1038/s41388-023-02860-x PMID: 37848624

Discovery of Benzodiazepine-Based Inhibitors of the E2 Enzyme UBCH10 from a Cell-Based p21 Degradation Screen.

Pelletier B, Duhamel S, Tambutet G, Jarvis S, Cléroux P, David M, Tanguay PL, Voisin L, James C, Lavoie R, Gareau Y, Flynn-Robitaille J, Lorca T, Ruel R, Marinier A, Meloche S

ACS chemical biology2023Senior author

DOI: 10.1021/acschembio.2c00909 PMID: 37097827

Live cell imaging platform for the mechanistic analysis of cell differentiation, migration and division

Co-investigatorNSERC2024Research Tools and Instruments

Principal investigators: Mader, Sylvie

Keywords: Biosensors; Cell differentiation; Cell division; Cell migration; Fluorescence; Live cell imaging; Morphogensis; Protein expression; Protein stability; Subcellular localization of proteins

$150,000

Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression

Nominated PICIHR2024Project Grant

Principal investigators: Meloche, Sylvain

Keywords: Basal-Like Breast Cancer; Chemoresistance; Erk3; Genetically-Engineered Mouse Models; Hypoxia; Map Kinases; Metastasis; Proteomics; Signal Transduction; Transcriptomics

$1,013,626

Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression

Nominated PICIHR2023Project Grant - PA: Breast Cancer Research

Principal investigators: Meloche, Sylvain

Keywords: Basal-Like Breast Cancer; Chemoresistance; Erk3; Genetically-Engineered Mouse Models; Genomics; Hypoxia; Map Kinases; Metastasis; Proteomics; Signal Transduction

$100,000

Reciprocal relationship between pH modulation and proteome remodeling

Principal investigatorNSERC2023Alliance Grants

Principal investigators: Meloche, Sylvain S

Keywords: Cell biology; Cell physiology; Membrane transporters; pH regulation; Proteome remodeling; Signal transduction; Ubiquitin-proteasome system

$25,000

Regulation of the mammalian proteome by pH

Principal investigatorNSERC2023Discovery Grants Program - Individual

Principal investigators: Meloche, Sylvain

Keywords: Cell biology; Genetic screens; pH regulation; Protein degradation; Proteome; Quantitative proteomics; Ubiquitin-proteasome system

$104,000

Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4

Nominated PICIHR2022Project Grant

Principal investigators: Meloche, Sylvain

Keywords: Cadd; Chemical Biology; Chemical Screens; Drug Development; Erk3/Erk4; Hit-To-Lead Chemistry; Map Kinases; Pharmacology; Preclinical Evaluation; Signal Transduction

$956,250

Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4

Nominated PICIHR2021Project Grant - PA: Breast Cancer Research

Principal investigators: Meloche, Sylvain

Keywords: Chemical Biology; Drug Development; Erk3/Erk4; Hit-To-Lead Chemistry; Map Kinases; Pharmacology; Preclinical Evaluation; Signal Transduction; Structural Biology; Synthetic Lethality

$100,000

See, Aim, Kill: A one-stop precise theranostic platform for in-situ detection and elimination of early-stage melanoma

Co-investigatorSSHRC2020New Frontiers in Research Fund - Exploration

Principal investigators: Liang, Jinyang

$250,000

Regulation of innate antiviral defenses through Interleukin-17 receptor D (IL-17RD)

Co-investigatorCIHR2020Project Grant

Principal investigators: Servant, Marc

Keywords: Fine-Tuning Of The Antiviral Innate Immune Response; Ikk Complex; Il-17rd; Interferon Regulatory Factors (Irf) Transcription Factors; Nf-Kb Transcription Factor; Repressor Functions; Rig-I-Like Receptors; Rna Viruses; Tbk1; Type I/Iii Interferons

$757,350

Role of the deubiquitylating enzyme USP17 in colorectal cancer

Principal investigatorCIHR2019Project Grant

Principal investigators: Servant, Marc; Meloche, Sylvain

Keywords: Colorectal Cancer; Deubiquitylating Enzymes (Dubs); Mouse Xenograft Models; Oncogene; Proliferation And Tumorigenic Growth; Quantitative Proteomics; Target Identification And Validation; Ubiquitin-Proteasome System (Ups); Usp17; Wnt/-Catenin (Ctnnb1) Signaling Pathway

$738,226

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Sylvain Meloche

Research

Latest papers

Latest funding

The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver &#x3b2;-catenin in colorectal cancer.

A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.

CDK12 inhibition reveals melanoma dependence on the RUNX1/CBF&#x3b2; complex for genomic stability.

Intracellular pH regulates ubiquitin-mediated degradation of the MAP kinase ERK3.

ERK3/MAPK6 promotes triple-negative breast cancer progression through collective migration and EMT plasticity.

Brain-wide mapping of immune receptors uncovers a neuromodulatory role of IL-17E and the receptor IL-17RB.

Syngeneic mouse model of YES-driven metastatic and proliferative hepatocellular carcinoma.

Phosphoproteomic analysis identifies supervillin as an ERK3 substrate regulating cytokinesis and cell ploidy.

A renaissance for YES in cancer.

Discovery of Benzodiazepine-Based Inhibitors of the E2 Enzyme UBCH10 from a Cell-Based p21 Degradation Screen.

Live cell imaging platform for the mechanistic analysis of cell differentiation, migration and division

Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression

Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression

Reciprocal relationship between pH modulation and proteome remodeling

Regulation of the mammalian proteome by pH

Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4

Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4

See, Aim, Kill: A one-stop precise theranostic platform for in-situ detection and elimination of early-stage melanoma

Regulation of innate antiviral defenses through Interleukin-17 receptor D (IL-17RD)

Role of the deubiquitylating enzyme USP17 in colorectal cancer

Frequent collaborators

Pierre Thibault

Guy Sauvageau

Ivan Topisirovic

Ivan Topisirovic

Anne Marinier

Nathalie Labrecque

Stephane Angers

Simon-Pierre Gravel

Daniel Lamarre

Mark Basik

Nathalie Grandvaux

Martin Sauvageau

Logan Walsh

Etienne Caron

Sonia Cellot

Trang Hoang

Nathalie Lamarche-Vane

Naguib Mechawar

Damien D'Amours

Brian Raught

Salah El Mestikawy

Mathieu Ferron

Benjamin Haibe-Kains

Nathalie Rivard

Anne-Marie Mes-Masson

Daniel Schramek

Nicolas Cermakian

Marc Therrien

Sylvie Lesage

Frank Sicheri

Nathalie Lamarche-Vane

The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer.

CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability.